Literature DB >> 2410915

Human plasma kallikrein and C1 inhibitor form a complex possessing an epitope that is not detectable on the parent molecules: demonstration using a monoclonal antibody.

A de Agostini, M Schapira, Y T Wachtfogel, R W Colman, S Carrel.   

Abstract

The inactivation of human plasma kallikrein (EC 3.4.21.8) by the inhibitor of activated complement component 1 (C1 inhibitor) induces the formation of a 1:1 stoichiometric kallikrein-C1 inhibitor complex and a proteolytically modified form of C1 inhibitor. We have produced a monoclonal antibody that recognizes the kallikrein-C1 inhibitor complex as well as modified C1 inhibitor but fails to react with virgin C1 inhibitor or native plasma kallikrein. This observation constitutes an unequivocal demonstration that the reaction between plasma kallikrein and C1 inhibitor leads to the emergence of an epitope that is undetectable on the parent enzyme and inhibitor molecules.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2410915      PMCID： PMC390525          DOI： 10.1073/pnas.82.15.5190

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  26 in total

1.  Human plasma prekallikrein: a rapid high-yield method for purification.

Authors:  C F Scott; C Y Liu; R W Colman
Journal:  Eur J Biochem       Date:  1979-10

2.  A simplified procedure for the purification of C1-inactivator from human plasma. Interaction with complement subcomponents C1r and C1s.

Authors:  A Reboul; G J Arlaud; R B Sim; M G Colomb
Journal:  FEBS Lett       Date:  1977-07-01       Impact factor: 4.124

3.  Trace polypeptides in cellular extracts and human body fluids detected by two-dimensional electrophoresis and a highly sensitive silver stain.

Authors:  C R Merril; R C Switzer; M L Van Keuren
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

4.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

5.  Emergence in plasma during activation of the coagulation or fibrinolytic systems of neoantigens, associated with the complexes of thrombin or plasmin with their inhibitors.

Authors:  D Collen
Journal:  Thromb Res       Date:  1974-12       Impact factor: 3.944

6.  Interaction of plasma kallikrein with the C1 inhibitor.

Authors:  I Gigli; J W Mason; R W Colman; K F Austen
Journal:  J Immunol       Date:  1970-03       Impact factor: 5.422

7.  Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in hageman factor-dependent fibrinolysis.

Authors:  R Mandle; A P Kaplan
Journal:  J Biol Chem       Date:  1977-09-10       Impact factor: 5.157

8.  Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate.

Authors:  B N Bouma; L A Miles; G Beretta; J H Griffin
Journal:  Biochemistry       Date:  1980-03-18       Impact factor: 3.162

9.  Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties.

Authors:  R W Colman; Y T Wachtfogel; U Kucich; G Weinbaum; S Hahn; R A Pixley; C F Scott; A de Agostini; D Burger; M Schapira
Journal:  Blood       Date:  1985-02       Impact factor: 22.113

10.  Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines.

Authors:  R S Accolla; S Carrel; J P Mach
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205
View more
  8 in total

1.  Biosynthesis of complement C1 inhibitor by Hep G2 cells. Reactivity of different glycosylated forms of the inhibitor with C1s.

Authors:  M H Prandini; A Reboul; M G Colomb
Journal:  Biochem J       Date:  1986-07-01       Impact factor: 3.857

2.  Inactivation of C-1 inhibitor by proteases: demonstration by a monoclonal antibody of a neodeterminant on inactivated, non-complexed C-1 inhibitor.

Authors:  J H Nuijens; C C Huijbregts; G M van Mierlo; C E Hack
Journal:  Immunology       Date:  1987-07       Impact factor: 7.397

3.  Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients.

Authors:  B L Zuraw; J G Curd
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

4.  Characterization of the StcE protease activity of Escherichia coli O157:H7.

Authors:  Thomas E Grys; Laura L Walters; Rodney A Welch
Journal:  J Bacteriol       Date:  2006-07       Impact factor: 3.490

5.  Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema.

Authors:  J Jackson; R B Sim; K Whaley; C Feighery
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

6.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

7.  A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase.

Authors:  A de Agostini; P A Patston; V Marottoli; S Carrel; P C Harpel; M Schapira
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

8.  Potentiation of C1 esterase inhibitor by StcE, a metalloprotease secreted by Escherichia coli O157:H7.

Authors:  Wyndham W Lathem; Tessa Bergsbaken; Rodney A Welch
Journal:  J Exp Med       Date:  2004-04-19       Impact factor: 14.307
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.